Hostname: page-component-5c6d5d7d68-wp2c8 Total loading time: 0 Render date: 2024-08-15T03:03:31.809Z Has data issue: false hasContentIssue false
  • English
  • Français

Comorbilidad de parkinsonismo y esquizofrenia en una paciente tratada con clozapina

Published online by Cambridge University Press:  12 May 2020

A. Urban ,
J. Libiger ,
L. Hosák  and
K. Kupka
A. Urban
Affiliation:
Departamento de Psiquiatría, Hospital Universitario, 500 05 Hradec Králové, República Checa
J. Libiger
Affiliation:
Departamento de Psiquiatría, Hospital Universitario, 500 05 Hradec Králové, República Checa
L. Hosák
Affiliation:
Departamento de Psiquiatría, Hospital Universitario, 500 05 Hradec Králové, República Checa
K. Kupka
Affiliation:
Instituto de Medicina Nuclear, Universidad Carlos, 1a Facultad de Medicina, Praga, República Checa
Get access

Resumen

La clozapina es el antipsicótico con menos probabilidad de inducir síntomas extrapiramidales (SEP). Presentamos un caso sorprendente de una paciente esquizofrénica tratada con clozapina que sufrió SEP. La tomografía computarizada por emisión de fotón simple (SPECT) reveló una densidad baja de transportadores de dopamina presinápticos en el cerebro de nuestra paciente. De esta manera, se confirmó un diagnóstic comórbido de enfermedad de Parkinson en la esquizofrenia. Esto nos ayudó a encontrar una estrategia terapéutica apropiada para nuestra paciente.

Keywords

EsquizofreniaParkinsonismoClozapinaSPECT
Type
Caso Clínico
Information
European Psychiatry (Ed. Española) , Volume 10 , Issue 8 , November 2003 , pp. 527 - 528
Copyright
Copyright © European Psychiatric Association 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Gerlach, J, Lublin, H, Peacock, L.Extrapyramidal symptoms during long-term treatment with antipsychotics, special focus on clozapine and DI and D2 dopamine antagonists. Neuropsychopharmacology 1996; 14: 35S–9S.CrossRefGoogle Scholar
Laakso, A, Bergman, J, Haaparanta, M, Vilkman, H, Solin, O, Syvalahti, E, et al.Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 2001; 52: 115–20.CrossRefGoogle ScholarPubMed
Laruelle, M, Abi-Dargham, A, van, Dyck C, Gil, R, D'Souza, DC, Krystal, J, et al.Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with P3I]p-CIT. Biol Psychiatry 2000; 47: 371–9.CrossRefGoogle Scholar
Lavalaye, J, Linszen, DH, Booij, J, Dingemans, PM, Reneman, L, Habraken, JB, et al.Dopamine transporter density in young patients with schizophrenia assessed with [123I]FP-CIT SPECT. Schizophr Res 2001; 47: 59–67.CrossRefGoogle Scholar
Schwarz, J, Scherer, J, Trenkwalder, C, Mozley, PD, Tatsch, K.Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy? Psychiatry Res 1998; 83: 23–8.CrossRefGoogle ScholarPubMed
Spivak, M, Mester, R, Abesgaus, J, Winterberg, N, Adlersberg, S, Gonen, N, et al.Clozapine treatment for neuroleptic-induced dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997; 58: 318–22.CrossRefGoogle ScholarPubMed